The drug treatment of 100 consecutive new patients admitted to a regional rheumatology centre was reviewed. Potential drug interactions were sought according to appendix one of the British National Formulary (September 1989) was significant an attempt was made to correct the drug treatment to avoid the interaction and the patient was followed up during the remainder of the admission (average duration three weeks) to determine whether the patient was able to tolerate this change without loss of therapeutic control. In the light of this, recommendations on future drug treatment were made to the family practitioner in the discharge summary.
Patients with arthritis often require several drugs to control their symptoms. Many take an analgesic for pain and an anti-inflammatory drug for stiffness. Patients with rheumatoid arthritis are likely to need a disease modifying drug added to this regimen. Many patients are elderly, requiring concomitant drugs for other diseases, so the potential for drug interaction is considerable. ' As a guide to practice in the United Kingdom the British National Formulary contains an appendix with a comprehensive list of potential drug interactions. was significant an attempt was made to correct the drug treatment to avoid the interaction and the patient was followed up during the remainder of the admission (average duration three weeks) to determine whether the patient was able to tolerate this change without loss of therapeutic control. In the light of this, recommendations on future drug treatment were made to the family practitioner in the discharge summary.
Results
Of 100 consecutive admissions studied, 70 were female and 30 were male. Their mean age was 59-6 years (range 20-84), and the principal rheumatic diagnosis on admission was rheumatoid arthritis (43), osteoarthritis (29), nonarticular rheumatism (seven), psoriatic arthritis (six), ankylosing spondylitis (five), polymyalgia rheumatica (three), other arthritis (seven). The mean plasma urea for the group was 6-56 mmol/l (range 2-1-18-4 mmol/l) and the mean serum creatinine for the group was 81[7 [smol/l (range 30-205 jsmol/l).
Eighty seven of the 100 patients were receiving three or more drugs. Thirty nine were receiving six or more drugs, 19 patients 10 or more drugs, and three were receiving 13 or more drugs. Non-arthritic conditions commonly present and requiring drug treatment included congestive cardiac failure, sleeplessness, iron deficiency, thyroid disorders and vitamin deficiencies, including folic acid and vitamin B-12.
At least one potential interaction was found in 55 of the 100 patients (mean 1-25 interactions per patient). Eight patients were at risk of three interactions, six patients at risk of four, one patient at risk of five, two patients at risk of six, and one patient at risk of 10.
As a result of full clinical history and examination it was judged that the drug interactions were only of clinical relevance in 11 of these 55 patients (table 1). Table 2 shows the drug combinations taken by these 11 patients and the clinical effects produced. Six of these patients were female and five male with a mean age of 72 years (range 57-84 years). Seven of these patients had rheumatoid arthritis, three ostoarthritis, and one polymyalgia rheumatica as their main rheumatic diagnosis. Mean urea concentration for the group was 9 7 mmol/l (range 4-5-16-4 mmol/l) and mean creatinine 111 tmol/l (range 39-168 pmol/l).
For six patients the adverse clinical effect was drowsiness and in each case it proved possible to relieve symptoms by simple changes in drugs.
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